

ROUND 1

We thank all the reviewers and editorial staff for their valuable input on our letter. Here is a point-by-point reponse to each issue raised in the peer review report:

Scientific Quality:

Reviewer #1:

Scientific Quality: Grade C (Good)

Language Quality: Grade B (Minor language polishing)

Conclusion: Minor revision

Specific Comments to Authors: This letter “Hepatocellular Carcinoma and Immunotherapy: Beyond Immune Checkpoint Inhibitors” that focused on immunotherapy of HCC and its biomarkers is interesting and easy to read. The authors have read the review focusing on immune aspects of hepatocellular carcinoma (HCC) by Mattos et al. and highly regarded the great value, on the basis of which they put forward the supplementary opinions on immune checkpoint inhibitors (ICIs) with structural table. The authors highlighted the role of promising immunotherapeutic modalities in HCC, such as glypican-3 (GPC3), multidrug resistance-associated protein 3 (MRP3), oncolytic virotherapy and cellular therapy, although most of these studies are still in phase 1 or Phase 2 clinical trials, they still bring hopes for the development of HCC immunotherapy. Besides, the authors emphasized the importance of identifying predictive biomarkers for immunotherapy response in HCC, establish predictive model may will play an important role in screening patients receiving immunotherapy, efficacy evaluation and prognosis prediction, while it is still needed to be validated repeatedly and widely in clinical practice.

Authors response: We thank the reviewer for their input and positive feedback.

Reviewer #2:

Scientific Quality: Grade E (Do not publish)

Language Quality: Grade D (Rejection)

Conclusion: Rejection

Specific Comments to Authors: None

Authors response: We thank the reviewer for their input.

Reviewer #3:

Scientific Quality: Grade D (Fair)

Language Quality: Grade B (Minor language polishing)

Conclusion: Minor revision

Specific Comments to Authors: The manuscript titled : "Hepatocellular Carcinoma and Immunotherapy: Beyond Immune Checkpoint Inhibitors" deserves to be published since it represents a very useful contribution to the medical literature. The authors have made a respectable effort

Authors response: We thank the reviewer for their input and positive feedback.

Language Polishing

The language of the manuscript has been edited and polished as requested.

Abbreviations

All abbreviations have been edited per the journal's guidelines.

Editorial Office Comments

(2) Science editor:

This letter pointed out other promising immunotherapeutic modalities such as vaccines in HCC. We wish all the coming trials become useful tools for future treatment of HCC.

Language Quality: Grade B (Minor language polishing)

Scientific Quality: Grade D (Fair)

Authors response: We thank the editor for their input and positive feedback.

(2) Company editor-in-chief:

I have reviewed the Peer-Review Report, full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Gastrointestinal Oncology, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors. Before final acceptance, authors are required to provide standard three-line tables, that is, only the top line, bottom line, and column line are displayed, while other table lines are hidden. The contents of each cell in the table should conform to the editing specifications, and the lines of each row or column of the table should be aligned. Do not use carriage returns or spaces to replace lines or vertical lines and do not segment cell content.

Authors response: We thank the editor for their input and positive feedback. We have edited our table into the requested three-line format. Other required specifications have been followed as well.

Author Information

We revised the author information per the guidelines for authorship format.

Note

The linked ICMJE conflict of interest disclosure form in the journal's email did not open. We downloaded the same form from the ICMJE website instead and filled it accordingly.

ROUND 2

the manuscript is in need for language edition

Authors response: Thank you for your comments. We apologize for the delayed response, we were waiting for the language editing service to be done. Please find the attached edited manuscript (With the table) by the language editing service as well as the certificate for the service.